SCHEDULE 13G/A: BlackRock Amends Schedule 13G, Disclosing 7.6% Passive Stake in Amgen Inc.

BlackRock, Inc. has filed an Amendment No. 15 to its Schedule 13G, reporting a 7.6% beneficial ownership stake in Amgen Inc.'s common stock as of March 31, 2025.

Summary

• BlackRock, Inc. reported beneficial ownership of 40,830,830 shares of Amgen Inc. common stock.
• This ownership represents 7.6% of Amgen Inc.'s total outstanding common stock.
• BlackRock holds sole voting power over 37,048,359 shares and sole dispositive power over all 40,830,830 shares.
• The filing confirms that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Amgen Inc.
• The filing is an Amendment No. 15 to a previously filed Schedule 13G, indicating an ongoing disclosure of their position.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. This is a routine regulatory disclosure of a significant passive stake by a major institutional investor, indicating continued confidence in the issuer without implying any active strategic involvement or negative sentiment.

Positives

• BlackRock's significant 7.6% stake in Amgen Inc. indicates continued confidence from a major institutional investor.
• The filing explicitly states that the investment is for ordinary course business, not for the purpose of changing or influencing control, which suggests a stable, passive investment.

Future Outlook

This Schedule 13G filing is a regulatory disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding Amgen Inc.'s future performance or BlackRock's investment strategy beyond the current ownership position.

Management Comments

• BlackRock, Inc. certified that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.

Industry Context

This filing reflects a routine disclosure by BlackRock, Inc., one of the world's largest asset managers, regarding its passive investment stake in Amgen Inc., a leading biotechnology company. Such disclosures are standard for large institutional investors managing diversified portfolios and typically indicate a significant, but non-controlling, holding within a fund's investment strategy, rather than a specific strategic shift within the biotechnology or pharmaceutical industry.

Comparison to Industry Standards

• As a Schedule 13G filing, this document primarily serves as a regulatory disclosure of beneficial ownership by a passive investor and does not provide operational or financial performance metrics for Amgen Inc. that would allow for direct comparison to industry standards or specific comparable companies/projects.
• The 7.6% stake held by BlackRock is a substantial institutional holding, which is common for large-cap companies like Amgen, and aligns with the portfolio diversification strategies of major asset managers globally.

Corporate Governance

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holding in Amgen Inc., potentially reinforcing investor confidence due to BlackRock's substantial, passive stake.
• Management: Confirms that a major institutional investor holds a significant passive stake, which is generally viewed positively as it indicates institutional support without intent to influence control.

Next Steps

• This filing does not specify any future actions or milestones for Amgen Inc. or BlackRock, Inc. beyond the regulatory disclosure requirements.

Key Dates

Recommendation

Keywords

Amgen Inc., BlackRock Inc., Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Biotechnology, Pharmaceuticals